A tool for treatment of VTE in patients with cancer as per intern’l guidelines

This application is available in English, French, Spanish, Portuguese, and Russian. The language of the app will be determined by the language setting of the user’s smartphone.

Based on international guidelines published in 2022, which were developed with methodological support from the Institut National du Cancer (INCa) in France and endorsed by the International Society on Thrombosis and Hemostasis (ISTH), this app is a practical step-by-step guide for the prophylaxis and treatment of venous thromboembolism (VTE: deep vein thrombosis (DVT), pulmonary embolism (PE), catheter-related thrombosis) in patients with cancer, including:

• Prophylaxis in hospitalized and ambulatory patients

• Recommendations for the treatment of both non-catheter and catheter-related VTE

• Specific recommendations related to special cancer situations

• Recommendations for initial, short-term, and long-term treatment

This treatment algorithm for anticoagulant use (low molecular weight heparins (LMWH), direct oral anticoagulants (DOAC), and vitamin K antagonists (VKA)) is intended for physicians and other healthcare professionals treating patients with cancer. It should not replace clinical judgement. It is based on clinical practice guidelines published in 2022:

Farge D*, Frere C*, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347.

While these guidelines rely on the best available evidence at the time of publication, the clinician is advised to use clinical judgement when making decisions about prophylaxis and treatment of cancer-associated thrombosis (CAT).

APP AUTHORS / STEERING COMMITTEE

Professor Dominique Farge (France) (Co-Chair)

Professor James Douketis (Canada) (Co-Chair)

Dr Syed Abutalib (United States)

Professor Cihan Ay (Austria)

Dr Darko Antic (Serbia)

Professor Henri Bounameaux (Switzerland)

Professor Benjamin Brenner (Israel)

Dr Dialina Brilhante (Portugal)

Dr Patricis Casais (Argentina)

Dr Jean M. Connors (United States)

Professor Corinne Frere (France)

Professor Maria Cecilia Guillermo Esposito (Uruguay)

Professor Takayuki Ikezoe (Japan)

Professor Alok A. Khorana (United States)

Right Honourable Professor Lord Ajay Kakkar (United Kingdom)

Professor Luis Meillon-Garcia (Mexico)

Professor Andres Munoz-Martin (Spain)

Professor Ingrid Pabinger (Austria)

Dr Pedro Henrique Prata (Brazil)

ABOUT ITAC-CME

The International Initiative on Thrombosis and Cancer (ITAC-CME) is the international section of the Groupe Francophone Thrombose et Cancer (GFTC). A multidisciplinary group, the members of ITAC-CME are clinicians and researchers from across the globe, led by a core group of GFTC members. Through education of physicians, nurses, and allied health professionals, ITAC-CME is committed to disseminating relevant and peer-reviewed prophylaxis and treatment guidelines for VTE in cancer that will help to reduce a substantial economic burden on health care systems and improve the lives of millions of patients worldwide.